DK175439B1 - Fremgangsmåde til aktivering af genteknologisk fremstillede og i prokaryoter udtrykte antistoffer - Google Patents

Fremgangsmåde til aktivering af genteknologisk fremstillede og i prokaryoter udtrykte antistoffer Download PDF

Info

Publication number
DK175439B1
DK175439B1 DK198905159A DK515989A DK175439B1 DK 175439 B1 DK175439 B1 DK 175439B1 DK 198905159 A DK198905159 A DK 198905159A DK 515989 A DK515989 A DK 515989A DK 175439 B1 DK175439 B1 DK 175439B1
Authority
DK
Denmark
Prior art keywords
mol
concentration
process according
mmol
reactivation
Prior art date
Application number
DK198905159A
Other languages
Danish (da)
English (en)
Other versions
DK515989A (da
DK515989D0 (da
Inventor
Helmut Lenz
Rainer Rudolph
Johannes Buchner
Original Assignee
Roche Diagnostics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roche Diagnostics Gmbh filed Critical Roche Diagnostics Gmbh
Publication of DK515989D0 publication Critical patent/DK515989D0/da
Publication of DK515989A publication Critical patent/DK515989A/da
Application granted granted Critical
Publication of DK175439B1 publication Critical patent/DK175439B1/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1133—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by redox-reactions involving cystein/cystin side chains
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • C12P19/28—N-glycosides
    • C12P19/30—Nucleotides
    • C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/867—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody produced via recombinant dna technology

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Saccharide Compounds (AREA)
DK198905159A 1988-10-17 1989-10-17 Fremgangsmåde til aktivering af genteknologisk fremstillede og i prokaryoter udtrykte antistoffer DK175439B1 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3835350A DE3835350A1 (de) 1988-10-17 1988-10-17 Aktivierung von gentechnologisch hergestellten, in prokaryonten exprimierten antikoerpern
DE3835350 1988-10-17

Publications (3)

Publication Number Publication Date
DK515989D0 DK515989D0 (da) 1989-10-17
DK515989A DK515989A (da) 1990-04-18
DK175439B1 true DK175439B1 (da) 2004-10-18

Family

ID=6365312

Family Applications (1)

Application Number Title Priority Date Filing Date
DK198905159A DK175439B1 (da) 1988-10-17 1989-10-17 Fremgangsmåde til aktivering af genteknologisk fremstillede og i prokaryoter udtrykte antistoffer

Country Status (12)

Country Link
US (1) US5077392A (fr)
EP (1) EP0364926B1 (fr)
JP (1) JPH0793879B2 (fr)
KR (1) KR920010873B1 (fr)
AT (1) ATE101650T1 (fr)
AU (1) AU609645B2 (fr)
CA (1) CA2000604C (fr)
DD (1) DD285613A5 (fr)
DE (2) DE3835350A1 (fr)
DK (1) DK175439B1 (fr)
ES (1) ES2061876T3 (fr)
IL (1) IL92012A (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5453363A (en) * 1985-10-23 1995-09-26 Boehringer Mannheim Gmbh Process for the activation of t-PA or Ing after genetic expression in prokaryotes
US5676947A (en) * 1989-02-07 1997-10-14 Boehringer Manneheim Gmbh Method for treating thromboembolic conditions using thrombolytically active proteins
DE4037196A1 (de) * 1990-11-22 1992-05-27 Boehringer Mannheim Gmbh Verfahren zur reaktivierung von denaturiertem protein
DE4105480A1 (de) * 1991-02-21 1992-08-27 Boehringer Mannheim Gmbh Verbesserte aktivierung von rekombinanten proteinen
AU3812993A (en) * 1992-03-24 1993-10-21 Synergen, Inc. Refolding and purification of insulin-like growth factor I
NZ261571A (en) * 1993-02-04 1997-03-24 Denzyme Aps Producing correctly folded proteins using multiple denaturation and renaturation cycles
EP0943690B1 (fr) * 1995-12-21 2006-11-29 Ajinomoto Co., Inc. Procede pour replier l'activine a humaine
AU2660397A (en) * 1996-04-05 1997-10-29 Board Of Regents, The University Of Texas System Methods for producing soluble, biologically-active disulfide bond-containing eukaryotic proteins in bacterial cells
US6083715A (en) * 1997-06-09 2000-07-04 Board Of Regents, The University Of Texas System Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells
EP1916020A3 (fr) 1997-08-15 2008-07-02 Chugai Seiyaku Kabushiki Kaisha Agents préventifs et/ou remèdes pour lupus érythémateux systémique contenant un anticorps de récepteur anti-IL-6 en tant qu'ingrédient actif
DE69934585T2 (de) * 1998-07-09 2007-10-25 BaroFold, Inc., Boulder Rückfaltung von protein-aggregaten und einschlussteilchen durch hohen druck
EP1077263A1 (fr) * 1999-07-29 2001-02-21 F.Hoffmann-La Roche Ag Procédé de préparation des protéines secrétées sous une forme pliée naturelle par co-sécrétion de chaperones
WO2001019970A2 (fr) * 1999-09-15 2001-03-22 Eli Lilly And Company Trypsine exempte de chymotrypsine
US6808902B1 (en) * 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
MXPA03003867A (es) 2000-10-31 2004-10-15 Univ Colorado Regents Desagregacion mejorada de proteina y replegamiento utilizando alta presion.
DE10105912A1 (de) * 2001-02-09 2002-08-14 Roche Diagnostics Gmbh Rekombinante Proteinase K
DE102005033250A1 (de) 2005-07-15 2007-01-18 Bioceuticals Arzneimittel Ag Verfahren zur Reinigung von G-CSF
MY143274A (en) * 2005-12-22 2011-04-15 Genentech Inc Recombinant production of heparin binding proteins
DE202006020194U1 (de) 2006-03-01 2007-12-06 Bioceuticals Arzneimittel Ag G-CSF-Flüssigformulierung
TWI476207B (zh) 2006-07-14 2015-03-11 Genentech Inc 重組蛋白之再摺疊
US20080161242A1 (en) * 2006-09-15 2008-07-03 Randolph Theodore W High pressure treatment of proteins for reduced immunogenicity
WO2011113601A1 (fr) 2010-03-17 2011-09-22 Biogenerix Ag Procédé permettant d'obtenir un g-csf humain recombinant biologiquement actif
HUP1200171A1 (hu) 2012-03-19 2013-09-30 Richter Gedeon Nyrt Módszerek polipeptidek elõállítására
US20160060291A1 (en) * 2012-03-30 2016-03-03 Biogenomics Limited Process for renaturation of polypeptides
US20150376228A1 (en) * 2013-02-22 2015-12-31 Biogenomics Limited Process for high efficiency refolding of recombinant proteins
WO2014167574A1 (fr) * 2013-03-22 2014-10-16 Biogenomics Limited Procédé pour l'isolation et la stabilisation d'intermédiaires clés pour un repliement à haute efficacité de protéines recombinantes
US10457716B2 (en) 2014-08-06 2019-10-29 University Of Notre Dame Du Lac Protein folding and methods of using same
CN110643595A (zh) * 2019-10-21 2020-01-03 黑龙江精益检测有限公司 一种对化学修饰后磁性固定化pla1再活化的方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4620948A (en) * 1982-12-22 1986-11-04 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
GR79124B (fr) * 1982-12-22 1984-10-02 Genentech Inc
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4634586A (en) * 1984-05-21 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Reagent and method for radioimaging leukocytes
ES8800957A1 (es) * 1985-02-22 1987-12-01 Monsanto Co Un metodo para la solubilizacion y renaturalizacion de proteina somatotropina
US4929444A (en) * 1985-05-28 1990-05-29 Burroughs Wellcome Co. Low pH pharmaceutical formulation containing t-PA
ZW14486A1 (en) * 1985-07-29 1986-10-22 Smithkline Beckman Corp Pharmaceutical dosage unit
DE3537708A1 (de) * 1985-10-23 1987-04-23 Boehringer Mannheim Gmbh Verfahren zur aktivierung von t-pa nach expression in prokaryonten
US4766205A (en) * 1985-11-13 1988-08-23 Beatrice Companies, Inc. Method for isolation of recombinant polypeptides in biologically active forms
FR2594845B1 (fr) * 1986-02-21 1989-12-01 Genetica Preparation par voie microbiologique de l'activateur tissulaire humain du plasminogene (t-pa) et conversion de l'enzyme ainsi obtenue en sa forme active
DE3611817A1 (de) * 1986-04-08 1987-10-15 Boehringer Mannheim Gmbh Verfahren zur renaturierung von proteinen

Also Published As

Publication number Publication date
JPH0793879B2 (ja) 1995-10-11
DK515989A (da) 1990-04-18
DK515989D0 (da) 1989-10-17
JPH02227090A (ja) 1990-09-10
ES2061876T3 (es) 1994-12-16
KR920010873B1 (ko) 1992-12-19
DD285613A5 (de) 1990-12-19
ATE101650T1 (de) 1994-03-15
EP0364926A2 (fr) 1990-04-25
DE58906984D1 (de) 1994-03-24
CA2000604A1 (fr) 1990-04-17
KR900006515A (ko) 1990-05-08
AU4293189A (en) 1990-04-26
US5077392A (en) 1991-12-31
IL92012A0 (en) 1990-07-12
EP0364926B1 (fr) 1994-02-16
CA2000604C (fr) 1999-07-06
EP0364926A3 (fr) 1991-05-02
AU609645B2 (en) 1991-05-02
DE3835350A1 (de) 1990-04-19
IL92012A (en) 1994-12-29

Similar Documents

Publication Publication Date Title
DK175439B1 (da) Fremgangsmåde til aktivering af genteknologisk fremstillede og i prokaryoter udtrykte antistoffer
Rudolph et al. In vitro folding of inclusion body proteins
US5593865A (en) Process for the activating of gene-technologically produced, heterologous, disulphide bridge-containing eukaryotic proteins after expression in prokaryotes
FI94876C (fi) Menetelmä aprotiniinin valmistamiseksi yhdistelmä-DNA-tekniikalla ja menetelmään soveltuva DNA, ilmentämisplasmidi ja isäntäsolu
US6583268B2 (en) Universal procedure for refolding recombinant proteins
Cardamone et al. Comparing the refolding and reoxidation of recombinant porcine growth hormone from a urea denatured state and from Escherichia coli inclusion bodies
JPH04218387A (ja) 遺伝子工学的に製造した、異種の、ジスルフイド結合を含有する真核蛋白質を原核における発現後に活性化する方法
EP1673393B1 (fr) Methodes, trousses et compositions permettant de developper et d'utiliser des anticorps monoclonaux specifiques d'antigenes presentant habituellement une faible antigenicite
Wei et al. Oxidative refolding of recombinant prochymosin
Haase‐Pettingell et al. Role for cysteine residues in the in vivo folding and assembly of the phage P22 tailspike
Marczinovits et al. An alternative purification protocol for producing hepatitis B virus X antigen on a preparative scale in Escherichia coli
King et al. Isolation, expression, and characterization of fully functional nontoxic BiP/GRP78 mutants
CN113687073B (zh) 一种非洲猪瘟病毒p54阻断ELISA抗体检测试剂盒及其应用
Lee et al. Bacterial expression and in vitro refolding of a single-chain fv antibody specific for human plasma apolipoprotein B-100
Boutelje et al. Human immunodeficiency viral protease is catalytically active as a fusion protein: characterization of the fusion and native enzymes produced in Escherichia coli
Maywald et al. Human pancreatic secretory trypsin inhibitor (PSTI) produced in active form and secreted from Escherichia coli
Burks et al. Rapid, High‐Yield Recovery of a Recombinant Digoxin Binding Single Chain Fv from Escherichia coli
Huth et al. Redox conditions for stimulation of in vitro folding and assembly of the glycoprotein hormone chorionic gonadotropin
KR20010103017A (ko) 글루코스 데히드로게나제 융합 단백질 및 발현계에서의그의 용도
JPH0284196A (ja) タンパク質の製造法
JP2001066309A (ja) ウイルス抗原の調製法
Kittler et al. [20] Monoclonal antibodies to vitamin B6
JP2001033449A (ja) ウイルス抗原の調製法
Belenkaya et al. The effect of thioredoxin and prochymosin coexpression on the refolding of recombinant alpaca chymosin
Tungekar et al. Understanding in-vivo refolding of antibody fragments (Fab): Biosimilar Ranibizumab a case study

Legal Events

Date Code Title Description
PUP Patent expired